Hydrazides in the reaction with hydroxypyrrolines: less nucleophilicity – more diversity
Dmitrii A. Shabalin ,
Evgeniya E. Ivanova,
Igor A. Ushakov,
Elena Yu. Schmidt and
Boris A. Trofimov
Dmitrii A. Shabalin
A. E. Favorsky Irkutsk Institute of Chemistry, Siberian Branch of the Russian Academy of Sciences, 1 Favorsky St, 664033 Irkutsk, Russian Federation
All articles from this author
Evgeniya E. Ivanova
Igor A. Ushakov
Elena Yu. Schmidt
Corresponding author email
Associate Editor: I. Baxendale
Beilstein J. Org. Chem. 2021, 17, 319–324. https://doi.org/10.3762/bjoc.17.29
Received 20 Nov 2020, Accepted 21 Jan 2021, Published 29 Jan 2021
Full Research Paper
Supp. Info
Expedient protocols for the synthesis of three types of highly functionalized azaheterocyclic scaffolds (dihydropyridazines, tetrahydropyridazines, and partially saturated tricyclic systems) from readily available hydroxypyrrolines and hydrazides are described. The directions of the transformation of a common initial intermediate, namely a Brønsted acid-activated hydroxypyrroline, depend on the reaction conditions and the structure of the hydrazides.
Keywords: hydrazides; pyridazines; pyrrolines; recyclization; ring expansion
Di- and tetrahydropyridazines are valuable heterocyclic motifs which are utilized as key fragments of influenza neuraminidase inhibitors [1], nonsteroidal progesterone receptor regulators [2,3], anti-inflammatory [4], antihypertensive and spasmolytic [5-7] agents (Figure 1). It is due to their prospects in drug design that a search for effective synthetic protocols to construct partially saturated pyridazine scaffolds is both highly topical and necessary.
Figure 1: Biologically active di- and tetrahydropyridazines.
Jump to Figure 1
Recently, we have developed a convenient approach to the 1,4-dihydropyridazine core based on the Brønsted acid-catalyzed regioselective recyclization of 5-hydroxypyrrolines (assembled in a one-pot manner from ketoximes and acetylene gas [8,9] or calcium carbide [10]) with hydrazines (Scheme 1) [11,12]. The reaction is operationally simple and tolerates a wide range of hydrazines including alkyl-, aryl-, and hetarylhydrazines [11] as well as semicarbazide and its derivatives [12].
Scheme 1: Recyclization of hydroxypyrrolines with hydrazine derivatives.
Jump to Scheme 1
However, the scope of this method with a special emphasis on the nature of hydrazine derivatives still remains obscure. Meeting this challenge becomes particularly important in view of the significance of the less nucleophilic hydrazides as N–N-bond containing starting materials in drug discovery [13-16].
Herein, we report how a lower nucleophilicity of the hydrazides diversifies the recyclization of 5-hydroxypyrrolines and results in the chemoselective formation of highly functionalized azaheterocyclic scaffolds. Such a short-cut to partially saturated azaheterocyclic scaffolds meets the interests of modern medicinal chemistry which today focuses on the study of partially saturated molecules because sp3 carbon centers make the molecules potentially chiral and 3D structured, which improves the odds for drug discovery [17].
On the basis of our previous works [11,12] the reaction of 3,3-dimethyl-5-hydroxy-2-phenyl-Δ1-pyrroline (1a) with an equimolar amount of benzohydrazide (2a) was initially performed in the presence of trifluoroacetic acid (TFA, 10 mol %) in refluxing acetonitrile for 3 h. Unexpectedly, 6-(2'-benzoylhydrazinyl)-1,4,5,6-tetrahydropyridazine 3aa was isolated in a 46% yield, while the anticipated 1,4-dihydropyridazine 4aa was not detected at all (Table 1, entry 1). Although the increase of the reaction time up to 5 h slightly improved the yield of tetrahydropyridazine 3aa (53%, entry 2 in Table 1), more efficient appeared to be the use of a two-fold excess of benzohydrazide (2a) that provided 3aa in 93% isolated yield after reflux for 3 h (Table 1, entry 4). With these optimal conditions for the synthesis of tetrahydropyridazine 3aa in hand, we next turned our attention to its transformation to 1,4-dihydropyridazine 4aa. Both the prolonged reflux for 6 h (Table 1, entry 5) and the addition of 100 mol % of TFA (Table 1, entry 6) did not significantly promote the 3aa→4aa transformation, that was apparently caused by the deactivation of the acid catalyst by ammonia, released in the preceding step (vide infra for the mechanism discussion). To prevent this process, a stepwise addition of TFA was tested (Table 1, entries 7–11). Finally, the best isolated yield of 1,4-dihydropyridazine 4aa (74%) was achieved by a two-step, one-pot protocol, comprising the initial recyclization of hydroxypyrroline 1a with 2 equiv of benzohydrazide (2a) in refluxing acetonitrile for 3 h in the presence of 10 mol % of TFA followed by the introduction of 140 mol % of TFA and additional reflux for 3 h (Table 1, entry 11).
Table 1: A study of the model reaction between hydroxypyrroline 1a and benzohydrazide (2a)a.
entry TFA loading (x mol %) time (h) yield of 3aab yield of 4aab
6 100 6 3aa:4aa = 78:22c
7 10 + 40 3 + 3 3aa:4aa = 55:45c
10 10 + 90 3 + 5 3aa:4aa = 22:78c
11 10 + 140 3 + 3 3aa:4aa = 3:97 (74%)b,c
aReaction conditions: hydroxypyrroline 1a (95 mg, 0.5 mmol), benzohydrazide (2a, 0.5 mmol for entries 1 and 2, 1.0 mmol for entries 3–11), TFA (x mol %), acetonitrile (3 mL), reflux; bif not stated otherwise, isolated yields are given; caccording to 1H NMR of the crude reaction mixture.
Next, the substrate scope and functional group tolerance of the protocols aimed to the chemoselective synthesis of di- and tetrahydropyridazines were investigated. Several features of the developed methods are noteworthy. It was found that all tested hydroxypyrrolines 1a–e and hydrazides 2a–g afforded the corresponding tetrahydropyridazines 3 (according to 1H NMR analysis of the crude reaction mixtures). However, due to the difficulties associated with their isolation and purification only few examples of analytically pure samples were obtained in 57–93% isolated yields (Scheme 2).
Scheme 2: Synthesis of tetrahydropyridazines 3.
When the same set of hydroxypyrrolines 1a–e and hydrazides 2a–g was subjected to the two-step, one-pot protocol, the desired 1,4-dihydropyridazines 4 were formed in 20–74% isolated yields (Scheme 3). Electron-rich hydrazides appeared to be good recyclization agents as was exemplified by the assembly of 1,4-dihydropyridazines 4ab and 4ag from 4-methylbenzohydrazide (2b) and acetohydrazide (2g) in 69% and 54% isolated yields, respectively. In contrast, the recyclization of hydroxypyrroline 1a with electron-deficient 4-nitrobenzohydrazide (2c) proceeded somewhat less efficiently to afford the corresponding 1,4-dihydropyridazine 4ac in 44% isolated yield. The structural fragment of the well-known antibiotic isoniazid (2f) was successfully incorporated in the tetrahydropyridazine core (the yield of 3af was 60%, Scheme 2), but only traces of the 1,4-dihydropyridazine 4af were detected following the two-step, one-pot protocol (Scheme 3). Apparently, the basic pyridine nitrogen atoms of intermediate 3af deactivate the acid catalyst, whilst the use of 3.4 equiv of TFA causes the full protonation of the pyridine rings thus making them strongly electron-deficient substituents that finally prevent an acid-catalyzed elimination of hydrazide 2f (vide infra for the mechanism discussion). Finally, the diverse hydroxypyrrolines 1b–e were tested in the studied reaction and the corresponding 1,4-dihydropyridazines 4ba–ea were obtained in 20–51% isolated yields.
Scheme 3: Synthesis of dihydropyridazines 4.
Interestingly, when hydroxypyrroline 1a reacted under a two-step, one-pot protocol with the hydrazides of salicylic (2d) and anthranilic (2e) acids having additional nucleophilic functions, the corresponding tricycles 5ad and 5ae were formed in 53% and 28% isolated yields, respectively (Scheme 4).
Scheme 4: Recyclization of hydroxypyrroline 1a with hydrazides 2d and 2e.
A proposed mechanism for the recyclization of hydroxypyrrolines 1 with hydrazides 2 is shown in Scheme 5. The protonation of the starting hydroxypyrroline 1 with TFA leads to the formation of cation A, which reacts with hydrazide 2 to give the pyrrolidine derivative B. The latter undergoes a ring opening with formation of the linear intermediate C. In comparison with alkyl-, aryl-, and hetarylhydrazines [11] as well as semicarbazide and its derivatives [12], the nucleophilicity of the internal nitrogen atom of hydrazide 2 is significantly reduced. As a result, the interception of the intermediate C by the second molecule of hydrazide 2 affords dihydrazone D (similar to previously observed in the recyclization with 2,4-dinitrophenylhydrazine [11]), which further cyclizes to tetrahydropyridazine 3. An acid-catalyzed elimination of hydrazide 2 from tetrahydropyridazine 3 completes the formation of 1,4-dihydropyridazine 4.
Scheme 5: A proposed mechanism for the recyclization of hydroxypyrrolines 1 with hydrazides 2.
In summary, an acid-catalyzed recyclization of hydroxypyrrolines (easily synthesized from ketoximes and acetylene) with hydrazides was studied. The reduced nucleophilicity of the hydrazides in comparison with other hydrazine derivatives constitutes the basis for the convenient chemoselective syntheses of highly functionalized azaheterocyclic scaffolds (di- and tetrahydropyridazines) with an acyl function at the nitrogen atom, thus having a substituent pattern similar to that of the known biologically active compounds of the pyridazine family. Moreover, the presence of other nucleophilic functions in the hydrazide component creates diversification points and enables more complex molecular architectures to be assembled that was demonstrated by the synthesis of partially saturated azatricyclic systems.
Supporting Information File 1: Experimental methods, compound characterization data, and copies of 1H and 13C NMR spectra.
Format: PDF Size: 2.3 MB Download
The spectral data were obtained with the equipment of the Baikal Analytical Center for collective use SB RAS. ESI-HRMS-TOF spectra were recorded at Shared Research Facilities for Physical and Chemical Ultramicroanalysis, Limnological Institute, SB RAS.
The reported study was funded by RFBR according to the research project No. 18-33-00089.
Zhang, L.; Williams, M. A.; Mendel, D. B.; Escarpe, P. A.; Chen, X.; Wang, K.-Y.; Graves, B. J.; Lawton, G.; Kim, C. U. Bioorg. Med. Chem. Lett. 1999, 9, 1751. doi:10.1016/s0960-894x(99)00280-2
Return to citation in text: [1]
Combs, D. W.; Reese, K.; Phillips, A. J. Med. Chem. 1995, 38, 4878–4879. doi:10.1021/jm00025a003
Combs, D. W.; Reese, K.; Cornelius, L. A. M.; Gunnet, J. W.; Cryan, E. V.; Granger, K. S.; Jordan, J. J.; Demarest, K. T. J. Med. Chem. 1995, 38, 4880–4884. doi:10.1021/jm00025a004
Chiou, G. C. Y.; Yao, Q. S.; Okawara, T. J. Ocul. Pharmacol. Ther. 1994, 10, 577–586. doi:10.1089/jop.1994.10.577
Frankowiak, G.; Meyer, H.; Bossert, F.; Heise, A.; Kazda, S.; Stoepel, K.; Towart, R.; Wehinger, E. 1,4-Dihydropyridazine compounds. U.S. Patent 4,348,395, Sept 7, 1982.
Loev, B.; Jones, H.; Shroff, J. R. N-Substituted 1,4-dihydropyridazines and pharmaceutical compositions. U.S. Patent 4,435,395, March 6, 1984.
Vogel, A. 4-(2,1,3-Benzoxadiazol-4-yl)-1,4-dihydropyridazine derivatives, their production and pharmaceutical compositions. U.S. Patent 4,491,581, Jan 1, 1985.
Shabalin, D. A.; Dvorko, M. Y.; Schmidt, E. Y.; Ushakov, I. A.; Trofimov, B. A. Tetrahedron 2016, 72, 6661–6667. doi:10.1016/j.tet.2016.08.088
Shabalin, D. A.; Dvorko, M. Y.; Schmidt, E. Y.; Protsuk, N. I.; Trofimov, B. A. Tetrahedron Lett. 2016, 57, 3156–3159. doi:10.1016/j.tetlet.2016.06.025
Shabalin, D. A.; Dubovtsev, A. Y.; Schmidt, E. Y.; Trofimov, B. A. ChemistrySelect 2020, 5, 3434–3437. doi:10.1002/slct.202000392
Shabalin, D. A.; Dvorko, M. Y.; Zolotareva, E. E.; Ushakov, I. A.; Vashchenko, A. V.; Schmidt, E. Y.; Trofimov, B. A. Eur. J. Org. Chem. 2017, 4004–4010. doi:10.1002/ejoc.201700589
Return to citation in text: [1] [2] [3] [4] [5]
Shabalin, D. A.; Ivanova, E. E.; Kuzmin, A. V.; Dvorko, M. Yu.; Schmidt, E. Yu.; Trofimov, B. A. Synthesis 2018, 50, 4982–4988. doi:10.1055/s-0037-1610239
Return to citation in text: [1] [2] [3] [4]
Narang, R.; Narasimhan, B.; Sharma, S. Curr. Med. Chem. 2012, 19, 569–612. doi:10.2174/092986712798918789
Verma, G.; Marella, A.; Shaquiquzzaman, M.; Akhtar, M.; Ali, M. R.; Alam, M. M. J. Pharm. BioAllied Sci. 2014, 6, 69–80. doi:10.4103/0975-7406.129170
Popiołek, Ł. Med. Chem. Res. 2017, 26, 287–301. doi:10.1007/s00044-016-1756-y
Wahbeh, J.; Milkowski, S. SLAS Technol. 2019, 24, 161–168. doi:10.1177/2472630318822713
Lovering, F.; Bikker, J.; Humblet, C. J. Med. Chem. 2009, 52, 6752–6756. doi:10.1021/jm901241e
1. Zhang, L.; Williams, M. A.; Mendel, D. B.; Escarpe, P. A.; Chen, X.; Wang, K.-Y.; Graves, B. J.; Lawton, G.; Kim, C. U. Bioorg. Med. Chem. Lett. 1999, 9, 1751. doi:10.1016/s0960-894x(99)00280-2
Go to reference 1
References 8,9
8. Shabalin, D. A.; Dvorko, M. Y.; Schmidt, E. Y.; Ushakov, I. A.; Trofimov, B. A. Tetrahedron 2016, 72, 6661–6667. doi:10.1016/j.tet.2016.08.088
9. Shabalin, D. A.; Dvorko, M. Y.; Schmidt, E. Y.; Protsuk, N. I.; Trofimov, B. A. Tetrahedron Lett. 2016, 57, 3156–3159. doi:10.1016/j.tetlet.2016.06.025
Go to references 8,9
11. Shabalin, D. A.; Dvorko, M. Y.; Zolotareva, E. E.; Ushakov, I. A.; Vashchenko, A. V.; Schmidt, E. Y.; Trofimov, B. A. Eur. J. Org. Chem. 2017, 4004–4010. doi:10.1002/ejoc.201700589
Go to reference 11
References 5-7
5. Frankowiak, G.; Meyer, H.; Bossert, F.; Heise, A.; Kazda, S.; Stoepel, K.; Towart, R.; Wehinger, E. 1,4-Dihydropyridazine compounds. U.S. Patent 4,348,395, Sept 7, 1982.
6. Loev, B.; Jones, H.; Shroff, J. R. N-Substituted 1,4-dihydropyridazines and pharmaceutical compositions. U.S. Patent 4,435,395, March 6, 1984.
7. Vogel, A. 4-(2,1,3-Benzoxadiazol-4-yl)-1,4-dihydropyridazine derivatives, their production and pharmaceutical compositions. U.S. Patent 4,491,581, Jan 1, 1985.
Go to references 5-7
4. Chiou, G. C. Y.; Yao, Q. S.; Okawara, T. J. Ocul. Pharmacol. Ther. 1994, 10, 577–586. doi:10.1089/jop.1994.10.577
2. Combs, D. W.; Reese, K.; Phillips, A. J. Med. Chem. 1995, 38, 4878–4879. doi:10.1021/jm00025a003
3. Combs, D. W.; Reese, K.; Cornelius, L. A. M.; Gunnet, J. W.; Cryan, E. V.; Granger, K. S.; Jordan, J. J.; Demarest, K. T. J. Med. Chem. 1995, 38, 4880–4884. doi:10.1021/jm00025a004
12. Shabalin, D. A.; Ivanova, E. E.; Kuzmin, A. V.; Dvorko, M. Yu.; Schmidt, E. Yu.; Trofimov, B. A. Synthesis 2018, 50, 4982–4988. doi:10.1055/s-0037-1610239
17. Lovering, F.; Bikker, J.; Humblet, C. J. Med. Chem. 2009, 52, 6752–6756. doi:10.1021/jm901241e
References 11,12
Go to references 11,12
10. Shabalin, D. A.; Dubovtsev, A. Y.; Schmidt, E. Y.; Trofimov, B. A. ChemistrySelect 2020, 5, 3434–3437. doi:10.1002/slct.202000392
References 13-16
13. Narang, R.; Narasimhan, B.; Sharma, S. Curr. Med. Chem. 2012, 19, 569–612. doi:10.2174/092986712798918789
14. Verma, G.; Marella, A.; Shaquiquzzaman, M.; Akhtar, M.; Ali, M. R.; Alam, M. M. J. Pharm. BioAllied Sci. 2014, 6, 69–80. doi:10.4103/0975-7406.129170
15. Popiołek, Ł. Med. Chem. Res. 2017, 26, 287–301. doi:10.1007/s00044-016-1756-y
16. Wahbeh, J.; Milkowski, S. SLAS Technol. 2019, 24, 161–168. doi:10.1177/2472630318822713
Go to references 13-16
All Thematic Issues
NaI/PPh3-catalyzed visible-light-mediated decarboxylative radical cascade cyclization of N-arylacrylamides for the efficient synthesis of quaternary oxindoles
Dan Liu, Yue Zhao and Frederic W. Patureau
Cyclometalated iridium complexes-catalyzed acceptorless dehydrogenative coupling reaction: construction of quinoline derivatives and evaluation of their antimicrobial activities
Hongling Shui, Yuhong Zhong, Renshi Luo, Zhanyi Zhang, Jiuzhong Huang, Ping Yang and Nianhua Luo
Lewis acid-catalyzed Pudovik reaction–phospha-Brook rearrangement sequence to access phosphoric esters
Jin Yang, Dang-Wei Qian and Shang-Dong Yang
Online Beilstein Talk with Hermann A. Wegner March 16 – Register for free!
Beilstein Glyco-Bioinformatics Symposium 2023 - June 20 to 22, 2023, Limburg, Germany
Take a look at the research you were most interested in last year
© 2021 Shabalin et al.; licensee Beilstein-Institut.
This is an Open Access article under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0). Please note that the reuse, redistribution and reproduction in particular requires that the author(s) and source are credited and that individual graphics may be subject to special legal provisions.
The license is subject to the Beilstein Journal of Organic Chemistry terms and conditions: (https://www.beilstein-journals.org/bjoc/terms)
Subscribe to our Latest Articles RSS-Feed.
Shabalin, D. A.; Ivanova, E. E.; Ushakov, I. A.; Schmidt, E. Y.; Trofimov, B. A. Beilstein J. Org. Chem. 2021, 17, 319–324. doi:10.3762/bjoc.17.29